GB202018412D0 - Malt-1 modulators ii - Google Patents

Malt-1 modulators ii

Info

Publication number
GB202018412D0
GB202018412D0 GBGB2018412.3A GB202018412A GB202018412D0 GB 202018412 D0 GB202018412 D0 GB 202018412D0 GB 202018412 A GB202018412 A GB 202018412A GB 202018412 D0 GB202018412 D0 GB 202018412D0
Authority
GB
United Kingdom
Prior art keywords
malt
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2018412.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exscientia Ltd
Original Assignee
Exscientia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exscientia Ltd filed Critical Exscientia Ltd
Priority to GBGB2018412.3A priority Critical patent/GB202018412D0/en
Publication of GB202018412D0 publication Critical patent/GB202018412D0/en
Priority to AU2021381009A priority patent/AU2021381009A1/en
Priority to CA3196526A priority patent/CA3196526A1/en
Priority to JP2023530634A priority patent/JP2023550122A/ja
Priority to CN202180078754.7A priority patent/CN116528857A/zh
Priority to EP21836594.8A priority patent/EP4247492A1/en
Priority to PCT/GB2021/053031 priority patent/WO2022106857A1/en
Priority to KR1020237021035A priority patent/KR20230112678A/ko
Priority to US18/253,572 priority patent/US20250051327A1/en
Priority to IL303036A priority patent/IL303036A/en
Priority to MX2023005928A priority patent/MX2023005928A/es
Priority to CONC2023/0007626A priority patent/CO2023007626A2/es
Priority to US19/424,423 priority patent/US20260109698A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Holo Graphy (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB2018412.3A 2020-11-23 2020-11-23 Malt-1 modulators ii Ceased GB202018412D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB2018412.3A GB202018412D0 (en) 2020-11-23 2020-11-23 Malt-1 modulators ii
MX2023005928A MX2023005928A (es) 2020-11-23 2021-11-23 Moduladores de malt-1.
PCT/GB2021/053031 WO2022106857A1 (en) 2020-11-23 2021-11-23 Malt-1 modulators
CA3196526A CA3196526A1 (en) 2020-11-23 2021-11-23 Malt-1 modulators
JP2023530634A JP2023550122A (ja) 2020-11-23 2021-11-23 Malt-1モジュレーター
CN202180078754.7A CN116528857A (zh) 2020-11-23 2021-11-23 Malt-1调节剂
EP21836594.8A EP4247492A1 (en) 2020-11-23 2021-11-23 Malt-1 modulators
AU2021381009A AU2021381009A1 (en) 2020-11-23 2021-11-23 Malt-1 modulators
KR1020237021035A KR20230112678A (ko) 2020-11-23 2021-11-23 Malt-1 조정자
US18/253,572 US20250051327A1 (en) 2020-11-23 2021-11-23 Malt-1 modulators
IL303036A IL303036A (en) 2020-11-23 2021-11-23 MALT-1 modulators
CONC2023/0007626A CO2023007626A2 (es) 2020-11-23 2023-06-09 Moduladores de malt-1
US19/424,423 US20260109698A1 (en) 2020-11-23 2025-12-18 Malt-1 modulators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2018412.3A GB202018412D0 (en) 2020-11-23 2020-11-23 Malt-1 modulators ii

Publications (1)

Publication Number Publication Date
GB202018412D0 true GB202018412D0 (en) 2021-01-06

Family

ID=74046962

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2018412.3A Ceased GB202018412D0 (en) 2020-11-23 2020-11-23 Malt-1 modulators ii

Country Status (12)

Country Link
US (2) US20250051327A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247492A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023550122A (cg-RX-API-DMAC7.html)
KR (1) KR20230112678A (cg-RX-API-DMAC7.html)
CN (1) CN116528857A (cg-RX-API-DMAC7.html)
AU (1) AU2021381009A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196526A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007626A2 (cg-RX-API-DMAC7.html)
GB (1) GB202018412D0 (cg-RX-API-DMAC7.html)
IL (1) IL303036A (cg-RX-API-DMAC7.html)
MX (1) MX2023005928A (cg-RX-API-DMAC7.html)
WO (1) WO2022106857A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔5,4-b〕吡啶malt-1抑制劑
EP4638458A1 (en) * 2022-12-23 2025-10-29 Janssen Pharmaceutica NV Malt1 inhibitors
JP2026526665A (ja) * 2023-06-30 2026-08-10 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤
CN122003418A (zh) * 2023-09-11 2026-05-08 薛定谔公司 作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物
WO2025223516A1 (zh) * 2024-04-24 2025-10-30 首药控股(北京)股份有限公司 一种抑制剂杂环化合物
WO2025223551A1 (en) * 2024-04-26 2025-10-30 Janssen Pharmaceutica Nv Formulations, crystalline forms and dosage regimens of a malt1 inhibitor
WO2025224298A1 (en) * 2024-04-26 2025-10-30 Janssen Pharmaceutica Nv Inhibitors of malt1 and methods of their use
WO2026003045A1 (en) 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Synthesis of a malt1 inhibitor
WO2026003043A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026003051A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Crystalline forms
WO2026003039A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026003049A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026017148A1 (zh) * 2024-07-19 2026-01-22 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012240D0 (en) 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
DE10132686A1 (de) * 2001-07-05 2003-01-16 Boehringer Ingelheim Pharma Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US7462614B2 (en) * 2003-04-01 2008-12-09 Smithkline Beecham Corporation Imidazotriazine compounds
PT2401256E (pt) * 2009-02-26 2013-05-13 Boehringer Ingelheim Int Compostos como antagonistas da bradicinina b1
GB0920382D0 (en) 2009-11-20 2010-01-06 Univ Dundee Design of molecules
WO2012143796A2 (en) * 2011-04-21 2012-10-26 Institut Pasteur Korea Anti-inflammation compounds
UY34616A (es) * 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
US9493481B2 (en) * 2012-02-23 2016-11-15 Vanderbilt University Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2015098991A1 (ja) * 2013-12-26 2015-07-02 東レ株式会社 N-アルキルアミド誘導体及びその医薬用途
JP6545197B2 (ja) 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用
US10124004B2 (en) * 2015-05-29 2018-11-13 Teijin Pharma Limited Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
WO2017027717A1 (en) * 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
EP3374361A1 (en) 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
JP6902040B2 (ja) * 2016-01-28 2021-07-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫チェックポイント阻害剤の効力を増強する方法
RU2019108717A (ru) * 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
JP2018135274A (ja) * 2017-02-20 2018-08-30 Agc株式会社 多環芳香族炭化水素を光触媒とするフルオロメチル基含有化合物の製造方法
JP6891047B2 (ja) * 2017-05-31 2021-06-18 国立大学法人 名古屋工業大学 光学活性トリフルオロメチル基含有アミノ酸誘導体の製造方法
WO2018226150A1 (en) * 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
BR112021009994A2 (pt) 2018-11-28 2021-08-17 Takeda Pharmaceutical Company Limited composto, e, medicamento
WO2022081995A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
WO2022081967A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof

Also Published As

Publication number Publication date
CO2023007626A2 (es) 2023-08-18
WO2022106857A1 (en) 2022-05-27
US20250051327A1 (en) 2025-02-13
EP4247492A1 (en) 2023-09-27
US20260109698A1 (en) 2026-04-23
AU2021381009A1 (en) 2023-06-08
IL303036A (en) 2023-07-01
KR20230112678A (ko) 2023-07-27
CA3196526A1 (en) 2022-05-27
CN116528857A (zh) 2023-08-01
JP2023550122A (ja) 2023-11-30
AU2021381009A9 (en) 2024-07-25
MX2023005928A (es) 2023-09-07

Similar Documents

Publication Publication Date Title
IL292156A (en) Transduced azacils as trmp8 modulators
PL3743406T3 (pl) Modulatory tmem16a
GB2594008B (en) Modulators
GB2601134B (en) Optical modulator
IL289890A (en) nlrp3 modulators
IL296413B2 (en) GPR52 modulator compounds
ZA202105847B (en) Mtroc modulators and uses thereof
GB202013282D0 (en) Optical modulator
IL307669A (en) PKC theta modulators
IL301007B1 (en) Gpr52 modulator compounds
EP3979998A4 (en) MODULATORS OF SWELL1-LRRC8 COMPLEX
GB2587795B (en) An electro-optic modulator
GB2585587B (en) Modulators
GB202115386D0 (en) Electro-absorption modulator
SI4401833T1 (sl) Gpr52-modulatorne spojine
GB2589174B (en) Electro-optic modulator
IL293272B1 (en) TRPM8 modulators
GB202018411D0 (en) Malt-1 modulators i
HK40081941A (en) Mettl3 modulators
HK40079716A (en) Mettl3 modulators
HK40101487A (en) Malt-1 modulators
DK4197885T3 (en) Hydraulisk styresystem
HK40072840A (en) Swell1-lrrc8 complex modulators
GB201918974D0 (en) Gpr52 modulator compounds
GB201918992D0 (en) GPR52 modulator compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)